Observed Signal · Oct 15, 2026 · Earnings Report · Source: Retail-News · Impact: 2/5 · Sentiment: Positive

DocMorris Q3 Revenue Up, Lifts 2026 Outlook

Executive Signal Summary

Swiss online pharmacy DocMorris reported a strong third quarter of 2026, with revenue growing 21.5% to CHF 342.7 million. The Rx (prescription) business surged 78.3% year-over-year, driven by strong demand for digital health services. The company reached adjusted EBITDA breakeven earlier than planned, posting CHF 0.6 million. As a result, DocMorris raised its full-year 2026 guidance, now expecting revenue growth of 12.5-15% and an adjusted EBITDA better than minus CHF 10 million. The digital services segment, including TeleClinic, retail media, and marketplace, grew 46.1% to CHF 13.9 million. Active customers rose to 13.1 million. The company also refinanced a convertible bond, extending maturity to 2031.

Polaris7 AgentPolaris7 Strategic Assessment
High Confidence

DocMorris is a major online pharmacy in DACH, and its performance reflects e-commerce trends in the health sector. However, it is not directly related to AdTech or advertising technology.

SIGNAL RADAR

Track Real-Time E-Commerce / Health Signals & Market Shifts

Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.

Start Monitoring
Verified primary sourcesAutomated briefingsInstant watchlist setup

Key Takeaways & Evidence Grounding

  • DocMorris Q3 2026 external revenue rose 21.5% to CHF 342.7 million.
  • Rx business grew 78.3% year-over-year; digital services up 46.1% to CHF 13.9 million.
  • Adjusted EBITDA reached CHF 0.6 million, hitting breakeven earlier than planned.
  • Full-year 2026 guidance raised: revenue growth now expected at 12.5-15%, EBITDA better than minus CHF 10 million.
  • Restructured CHF 49.6 million convertible bond, extending maturity to 2031.
Primary Source Grounding & Direct Attribution
Direct Origin Attribution
Primary Reporting: Retail-News•Published: Oct 15, 2026
Original Coverage Title: “DocMorris steigert Quartalsumsatz deutlich und verbessert Ergebnisausblick”

Related Market Signals & Shifts

Recent verified developments and strategic activity across this market segment.

FinancialsAug 19, 2026

DocMorris Raises 2026 Guidance After Strong Rx Growth

DocMorris reported improved revenue and operating results for the first half of 2026 and raised its full-year guidance following strong growth in prescription drugs (Rx) and digital services. External revenue rose 12.5% to CHF 627.8m, reported revenue increased 13.4% to CHF 599.2m. Adjusted EBITDA narrowed to a loss of CHF 10.9m (improved by CHF 17.9m), while unadjusted EBITDA was CHF -20.0m including CHF 7.6m of extraordinary charges related to an AI-first strategy and a site closure. Rx revenue grew ~38% year-to-date (45.8% in Q2) and DocMorris now expects ~40% Rx growth for 2026; Digital Services revenue jumped 71.4%. Management still targets an EBITDA breakeven in H2 2026 and expects free cash flow to reach breakeven in 2027.

Read assessment
Earnings ReportOct 29, 2026

Redcare Pharmacy Q3 Revenue Up 18%, E-Prescription Business Grows

Redcare Pharmacy, the online pharmacy group, reported a strong third quarter 2026, with revenue increasing 18% to €847 million. The main growth driver was the prescription drug business in Germany, which grew 56% to €197 million. Group-wide Rx revenue increased 31% to €358 million. Adjusted EBITDA rose 68% to €28.7 million, with the margin improving to 3.4%. The company achieved a net profit of €1 million for the second consecutive quarter. Active customers grew by 11% year-over-year to 15.2 million, with 500,000 added in Q3 alone. Despite a slight decline in gross margin to 21.8%, the company benefited from lower distribution costs and marketing spend. The DACH region's adjusted EBITDA margin improved to 4.2%. Management confirmed the 2026 guidance: group revenue growth of 16-18% and adjusted EBITDA margin of 2.5-3.0%.

Read assessment
E-Commerce / RetailSep 28, 2026

Redcare Pharmacy Raises 2026 Guidance on Strong Rx Business

Redcare Pharmacy, a German online pharmacy, has raised its full-year 2026 guidance for the second time, driven by strong growth in its prescription (Rx) business in Germany. The company now expects Rx revenue of €730-760 million, up from a previous forecast of €680-720 million, representing growth of 45-51% year-over-year. Group revenue growth is now projected at 16-18%, up from 15-17%. This follows a strong third quarter, with German Rx sales up 56% year-over-year and September alone up 51%. The non-Rx business is stabilizing after a weak July, with growth expected at 10-12%. The adjusted EBITDA margin forecast remains at 2.5-3.0%. Customer satisfaction remains high, with an e-Rx NPS of 80 points in August, six points above last year. Full Q3 results will be published on October 29, 2026.

Read assessment
Executive Briefing & Watchlist

Receive all future signals for E-Commerce / Health in your executive briefing

Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.

Daily primary source scansCurated executive briefingsUnsubscribe anytime